Related Experiment Videos
Volatile substances in blood serum: profile analysis and quantitative determination
Journal of Chromatography
|November 11, 1977
Summary
Volatile compounds like alcohols and ketones in blood serum can indicate health status. Elevated levels of 4-heptanone in patients with chronic renal insufficiency suggest its potential as a biomarker.
Area of Science:
- Analytical Chemistry
- Clinical Chemistry
- Biochemistry
Background:
- Volatile organic compounds (VOCs) in blood serum are increasingly recognized for their diagnostic potential.
- Alcohols, ketones, and aldehydes are among the key VOCs that can be detected and quantified.
- Gas chromatography and mass spectrometry are powerful tools for analyzing these complex mixtures.
Purpose of the Study:
- To develop and apply methods for the quantitative determination of specific volatile substances in human blood serum.
- To investigate the potential of these volatile compounds as biomarkers for chronic renal insufficiency.
Main Methods:
- Gas chromatography coupled with mass fragmentography (GC-MF) was employed for selective and sensitive detection of volatile compounds.
- A 5-ml blood serum sample was utilized to obtain comprehensive volatile profiles.
- Quantitative analysis of 4-heptanone involved an extraction and GC-MF procedure.
- Direct injection of serum was used for the quantitative measurement of ethanol and acetone.
Main Results:
- Normal serum exhibited 4-heptanone concentrations ranging from 10-50 nmole/l.
- Patients with chronic renal insufficiency showed 10- to 40-fold higher concentrations of 4-heptanone compared to normal individuals.
- Acetone levels in patients ranged from 25-85 mumole/l, and ethanol levels ranged from 10-170 mumole/l.
Conclusions:
- The study successfully quantified key volatile compounds in blood serum using advanced analytical techniques.
- Elevated serum 4-heptanone levels are strongly associated with chronic renal insufficiency, highlighting its potential as a diagnostic biomarker.
- Further research is warranted to explore the full clinical utility of these volatile biomarkers.